Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-014721
Filing Date
2025-04-21
Accepted
2025-04-21 16:05:50
Documents
21
Period of Report
2025-05-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20044209x2_def14a.htm   iXBRL DEF 14A 1109325
6 ny20044209x2_pc01.jpg GRAPHIC 646372
7 ny20044209x2_pc02.jpg GRAPHIC 499978
8 ny20044209x4_pvpchart01.jpg GRAPHIC 95232
9 sig_charlesnewton.jpg GRAPHIC 17313
  Complete submission text file 0001140361-25-014721.txt   5610937

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA lyel-20250515.xsd EX-101.SCH 3209
3 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE lyel-20250515_def.xml EX-101.DEF 2763
4 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE lyel-20250515_lab.xml EX-101.LAB 1857
5 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE lyel-20250515_pre.xml EX-101.PRE 5462
24 EXTRACTED XBRL INSTANCE DOCUMENT ny20044209x2_def14a_htm.xml XML 470888
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40502 | Film No.: 25853171
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)